Published in final edited form as:

J Org Chem. 2015 December 18; 80(24): 12300–12310. doi:10.1021/acs.joc.5b02203.

Absence of Stereodirecting Participation by 2-*O*-Alkoxycarbonylmethyl Ethers in 4,6-*O*-Benzylidene-Directed Mannosylation

Peng Wen and David Crich

Department of Chemistry, Wayne State University, Detroit, MI 48202, USA

David Crich: dcrich@chem.wayne.edu

Abstract

The preparation of a series of mannopyranosyl donors carrying 2-*O*-(2-oxoalkyl) ethers and their use in glycosylation reactions is described. The formation of cyclic products with the simple 2-*O*-phenacyl ether and with the 2-*O*-(*t*-butoxycarbonylmethyl) ether establishes the stereoelectronic feasibility of the participation in such systems. The high β -selectivities observed with the bis-trifluoromethyl phenacyl ether indicate that participation can be suppressed through the introduction of electron-withdrawing substituents. The high β -selectivities and absence of cyclic products observed with the 2-*O*-(methoxycarbonylmethyl) ether excludes the effective participation of esters through six-membered cyclic intermediates in this series. The results are discussed in terms of the conformation of cyclic dioxenium ions (*E,E*-, *E,Z*- or *Z,Z*,-) and in the context of “neighboring group” participation by non-vicinal esters in glycosylation. Methods for the deprotection of the 2-*O*-phenacyl and 2-*O*-(methoxycarbonylmethyl) ethers are described.

Introduction

Stereodirecting neighboring group participation by vicinal esters in the nucleophilic substitution reactions is one of the core concepts of modern organic chemistry,¹ and has been one of the most enduring themes of carbohydrate chemistry and glycosylation reactions.^{2–4} Such participation proceeds through the formation of an intermediate dioxalenium ion,^{5–7} which is captured by the acceptor alcohol to afford the orthoester as the kinetic product. Subsequent acid or Lewis acid-mediated rearrangement then provides the 1,2-*trans*-glycoside.^{8–11} The β -gluco- and α -mannopyranosides owe their relatively facile synthetic availability to stereodirecting neighboring group participation. When participation is associated with kinetic acceleration of the substitution process, the phenomenon is known as anchimeric assistance.¹²

There have been many attempts to extend the phenomenon of stereodirecting neighboring group participation in glycosylation to the use of six or larger-membered cyclic

Correspondence to: David Crich, dcrich@chem.wayne.edu.

Supporting Information Available. Full experimental details, copies of ¹H and ¹³C NMR spectra for all new compounds, and Cartesian co-ordinates and total electronic energies for computed structures. This information is available free of charge via the internet at <http://pubs.acs.org>.

intermediates by more remote esters or by other functional groups.¹³ With certain notable exceptions for which cyclic intermediates have been demonstrated spectroscopically or crystallographically,^{14–21} the evidence for such effects typically is limited to often modest changes in anomeric selectivity and comparisons with selectivities observed in the presence of non-participating groups.^{13,22–31} Alternative explanations are always available for such examples, most notably protecting group-induced changes in: i) conformation;^{32–34} ii) through space stabilization of oxocarbenium ions;^{35–41} iii) in the degree of association of the leaving group with the anomeric carbon;^{42–43} iv) and the extent of pre-association of the donor and acceptor through hydrogen bonding.^{44–45} By means of isotopic labelling experiments Wilen demonstrated in simple model systems that participation by esters through six- and even seven-membered ring intermediates is possible albeit significantly retarded with respect to neighboring group participation through five-membered dioxalenium ions.⁴⁶ Yu and coworkers, using an isotopic labelling experiment, demonstrated initial participation via a seven-membered ring by the 4-*O*-ester in the formation of a bridged 1,2,4-*O*-orthoacetyl α -glucopyranose derivative on activation of per-*O*-acetyl glucopyranosyl donor.¹⁸ Computational studies have also been advanced in support of participation by ester groups through the formation of six-membered and larger ring intermediates.²⁷ Notwithstanding these contributions, the question of the relevance of such intermediates under typical glycosylation conditions mostly remains unanswered.

In our laboratory we introduced the *O*-*t*-butyloxycarbonyl and *O*-(*o*-carboxybenzoate) benzoate groups as probes for participation under typical glycosylation conditions and found no evidence in support of intermediates bridging the anomeric position and either the mannopyranose 3- and 4-positions, the galactopyranose 4-position, and the glucopyranose 6-position in pyranosyl donors carrying benzyl ethers at all other positions.⁴⁷ An isotopic labelling experiment also failed to provide evidence for participation by a 4-*O*-benzoate in the galactopyranose series under the conditions employed.⁴⁷ In contrast the bridged intermediate resulting from participation by a Boc group at the 3-position in an allopyranosyl donor was readily trapped and isolated.⁴⁷

In this Article we turn our attention to substituted 2-*O*-(2-oxoethyl) ethers in the mannopyranose series as probes of participation by carbonyl groups (in ketones and esters) through six-membered cyclic intermediates. We report that the 2-*O*-phenacyl ether traps the activated glycosyl donor through formation of a six-membered intermediate and that this participation can be readily suppressed by the introduction of electron-withdrawing groups to the phenacyl system. In contrast the 2-*O*-(methoxycarbonylmethyl) ether does not participate and to the contrary permits the formation of β -mannopyranosides in high yield.

Results

Synthesis

Consistent with earlier results⁴⁸ phenacyl ethers were best introduced by alkoxide etherification with 2-phenylallyl bromides followed by oxidative cleavage of the alkene, rather than by direct reaction of the alkoxide with phenacyl bromides. Thus, treatment of thioglycoside **1** with sodium hydride and a series of 2-arylallyl bromides gave the 2-*O*-(2-arylallyl) ethers **2–4** in good yield (Scheme 1). Subsequent ozonolytic cleavage of the alkene

in dichloromethane/methanol mixtures at $-78\text{ }^{\circ}\text{C}$ gave the requisite ketones **5–7** together with the sulfoxides **8–10** (Scheme 1). With the phenyl and trifluorophenylalkenes **5** and **6** ozonolytic cleavage of the alkene was the dominant reaction pathway and the sulfoxides were only minor products, however, with the more electron-deficient bis(trifluoromethyl)phenyl alkene **7** the sulfoxide **10** was the major product. When **7** was exposed to an excess of ozone and the reaction mixture stirred at $-78\text{ }^{\circ}\text{C}$ for a longer time (0.5 h) **10** was obtained in 69% yield. All three sulfoxides obtained from the ozonolytic cleavage were obtained as essentially single diastereomers to which we assign the S_R configuration indicated consistent with peroxide-mediated oxidations of related α -mannopyranosyl thioglycosides.^{49–51} This assignment was corroborated by the oxidation of **5**, **6**, and **7** with *m*CPBA in dichloromethane at $-78\text{ }^{\circ}\text{C}$, when the identical sulfoxides **8**, **9**, and **10** were obtained in high yield and selectivity (Scheme 1).

Comparable 2-*O*-(methoxycarbonylmethyl) and 2-*O*-(*t*-butoxycarbonylmethyl) thioglycosides **11** and **12** were obtained by alkylation of the sodium salt of **1** with methyl bromoacetate and *t*-butyl bromoacetate, respectively (Scheme 2). Oxidation of **11** and **12** with *m*CPBA then gave the sulfoxides **13** and **14** again as a single diastereomers, together with the sulfone **15** in the case of the methyl ester (Scheme 2).

Attempted coupling of the phenacyl derivative **5** with adamantanol **16** on activation with diphenyl sulfoxide (DPSO) and triflic anhydride in the presence of the hindered non-nucleophilic base 2,4,6-tri-*tert*-butylpyrimidine (TTBP) in dichloromethane at $-78\text{ }^{\circ}\text{C}$ gave a complex reaction mixture in which we were unable to identify the anticipated glycosylation product **19** by ESI-mass spectrometry of the reaction mixture. The major isolated product from this reaction mixture was the tricyclic product **22**, which was isolated in 33% yield (Table 1). With the 4-trifluoromethylphenacyl derivative **6**, under the same conditions conversion was low and similarly complex reaction mixtures were observed in which the glycoside was not identified. Preactivation of the corresponding sulfoxide **9** with triflic anhydride at $-78\text{ }^{\circ}\text{C}$ in dichloromethane in the presence of TTBP followed by addition of the rhamnose 4-ol **17** also gave complex reaction mixtures as demonstrated by TLC and mass spectrometric analysis. Accordingly, the mono-trifluoromethyl substituted donors **6** and **9** were not pursued further. Activation of the 2,4-bis(trifluoro)phenylacetyl thioglycoside **7** with 1-benzenesulfonyl piperidine (BSP) and triflic anhydride in the presence of TTBP in dichloromethane at $-78\text{ }^{\circ}\text{C}$, followed by addition of 1-adamantanol gave the glycoside **20** in 62% yield as a 3.8:1 β : α mixture (Table 1, entry 2). Activation of the corresponding sulfoxide **10** with triflic anhydride at $-78\text{ }^{\circ}\text{C}$ followed by addition of 1-adamantanol also gave glycoside **20** in 62% yield, but with selectivity of 7.9:1 in favor of the β -anomer (Table 1, entry 3). With the rhamnosyl acceptor **17**, the sulfoxide donor **10** gave 57% of the glycoside **23** as a single β -anomer (Table 1, entry 4). Coupling of the methoxycarbonylmethyl substituted thioglycoside **11** with acceptors **16–18** with activation by BSP under preactivation conditions gave the glycosides **21**, **24**, and **26** in good yield, with selectivities ranging from 2.6:1 for the less reactive acceptor **18** to complete with the rhamnoside **17** (Table 1, entries 5–7). Preactivation of the sulfoxide **13**, derived from thioglycoside **11**, followed by addition of acceptors **17** and **18** gave the glycosides **24** and **26** in good yield both as single diastereomers (Table 1, entries 8 and 9). Preactivation of the

corresponding *t*-butoxycarbonylmethyl sulfoxide **14** with triflic anhydride followed by addition of the rhamnosyl acceptor **17** resulted in a 70% isolated yield of the lactone **27**, together with 3% of the glycoside **25** in the form of the β -anomer (Table 1, entry 10). Careful examination of this latter reaction mixture gave no indication of the formation of the α -anomer of **25**. Likewise, no evidence was found for the formation of the *trans*-fused lactone corresponding to **27**, whose central pyranose ring would be expected to adopt a twist boat conformation by analogy with related compounds described previously,^{52–53} or of hydroxy acids arising from the hydrolytic ring opening of **27** and its putative *trans*-fused isomer. Although not isolated and fully characterized, a number of byproducts arising from the modification of acceptor **17**, glycoside **25**, and lactone **27** by one or more of the benzenesulfinyl, benzenesulfonyl, and *t*-butyl based electrophiles generated in the course of the main reaction pathway, were revealed in this reaction mixture by mass spectrometry. Comparable results were obtained on activation of the thioglycoside **12** with the BSP/Tf₂O and DPSO/Tf₂O combinations, with the lactone **27** as the major product and no indication of the formation of its *trans*-fused isomer.

Selective removal of the phenacyl-type protecting group following glycosylation was demonstrated by treatment of **23** with samarium iodide in THF when the known glycoside **28** was isolated in 75% yield (Scheme 3). Removal of the methoxycarbonylmethyl group was exemplified by treatment of **24** with potassium hexamethyldisilazide in THF at -78 °C followed by addition of the Davis camphorylsulfonyl oxaziridine,⁵⁴ when glycoside **28** was isolated in 64% yield (Scheme 3). In view of the minor amount of the glycoside **25 β** obtained from the coupling of **14** and **17** (Table 1, entry 10), an authentic sample was obtained by alkylation of **28** with *t*-butoxy bromoacetate and proved identical in all respects (Scheme 3).

Discussion

Effective glycosylation with the 2-*O*-phenacyl donors **5**–**10** necessitated the inclusion of two trifluoromethyl moieties on the phenacyl group: relatively high glycosylation yields, generally clean reaction mixtures, and β -selectivity were obtained with the bis(trifluoromethyl)phenacyl system (Table 1, entries 2–4). In contrast, the unsubstituted (Table 1, entry 1) and mono(trifluoromethyl)phenacyl systems gave complex reaction mixtures. This pattern of results indicates competing nucleophilic reactivity of the phenacyl system with electrophilic species in the glycosylation reaction mixtures that can be minimized on introduction of two strong electron-withdrawing groups, recalling the classical work of Lemieux on participation by mono-, di-, and trichloroacetates.⁵⁵ The tricyclic compound **22** formed on activation of the phenacyl thioglycoside **5** (Table 1, entry 1) is one example of the numerous side reactions that can be envisaged between this class of protecting group and the type of electrophiles present during glycosylation. Mechanistically tricycle **22** can be viewed as the product of initial sulfenylation of the enolized ketone followed by nucleophilic attack of the ketone (or enol) at the anomeric position. Alternatively, **22** can be envisaged as being the result of participation by the phenacyl group, followed by enolization, reaction of the enol with an electrophilic byproduct of the activation process, and deprotonation. Whether sulfenylation occurs before or after ring closure, the formation of the tricyclic compound **22** from the 2-*O*-phenacyl system **5** firmly establishes the possibility of participation through a six-membered cyclic intermediate in the system under study. Further precedent for cyclization onto the anomeric center with formation of a six-membered ring is found in the intramolecular Sakurai reaction of mannosyl 2-*O*-(2-trimethylsilylmethyl) ethers employed as cation clocks^{52–53} and in the intramolecular Freidel-Crafts reaction of a mannosyl oxocarbenium ion onto a 2-*O*-benzyl ether.⁵⁶ Albeit accessed by an entirely different method, closely related tricyclic systems have also been described previously by Franck and coworkers.^{57–58}

The incorporation of two electron-withdrawing trifluoromethyl groups as in the thioglycoside **7** and the related sulfoxide **10** gave clean glycosylation reactions that demonstrated high β -selectivity (Table 1, entries 2–4). The β -selective processes observed with donors **7** and **10** (Table 1, entries 2–4) exclude the possibility of participation by the bis(trifluoromethyl)ketone as a major reaction pathway in their glycosylation reactions.

Glycosylations conducted with the 2-*O*-(methoxycarbonylmethyl) protected donors **11** and **13** (Table 1, entries 5–9) were all β -selective and high yielding consistent with the absence of effective participation by the ester, and with the general compatibility of esters with a wide variety of glycosylation reaction conditions. An example demonstrating only modestly β -selective glycosylation involved coupling to the less reactive glucose 4-OH acceptor **18** under the BSP conditions (Table 1, entry 7), suggesting a lower degree of association in the transition state.^{43,59} Attempted glycosylation with the 2-*O*-(*t*-butoxycarbonylmethyl) protected donors **12** and **14** resulted in the formation of the lactone **27** as the major product along with minor amounts of the β -anomer of the anticipated glycoside (Table 1, entry 10). This observation reinforces the conclusion drawn from the use of the 2-*O*-phenacyl donors **5**–**10**, that participation through a six-membered ring in the manner anticipated is stereoelectronically feasible. The contrast between the results observed with the 2-*O*-

(methoxycarbonylmethyl) and the 2-*O*-(*t*-butoxycarbonylmethyl)-protected systems and the predominant formation of β -glycosides in both cases indicates that for the alkoxycarbonylmethyl systems the association between the ester and the anomeric center is i) weak, transient, and insufficient to influence the stereochemical outcome of the glycosylation reaction, and ii) only revealed when cleavage of a *t*-C-O bond is possible, reflecting the difference in stability of the *t*-butyl and methyl cations.⁶⁰

The absence of effective participation by the ester moiety in donors **11–14**, despite the ideal *trans*-diaxial relationship of the ester and the anomeric leaving group, invites careful comparison of the putative intermediates arising from participation by alkoxycarbonylmethyl ethers and from classical participation by esters. Classical neighboring group participation by esters affords planar⁵ five-membered cyclic dioxalenium ions in which the *Z,Z*-configuration is enforced on the dialkoxy carbenium ion (Figure 1A), whereas participation by the alkoxycarbonylmethyl groups in **11–14** would afford six-membered cyclic dioxenium ions, in an envelope conformation, with the dialkoxy carbenium configured *E,Z* or *E,E* (Figs 1B and 1C) according to the conformation (*trans* or *cis*, respectively) of the ester taking part in the cyclization.

In the absence of constraints the *E,Z*-configuration of dialkoxycarbenium ions is considered to the most stable of the three possibilities from both steric and stereoelectronic perspectives.⁶¹ This consideration is supported by NMR studies^{62–64} and by DFT calculations, which suggest that the *E,Z*-configuration of simple dialkoxycarbenium ions is >2.5 kcal.mol⁻¹ more stable than the *E,E*-configuration. Furthermore, alkylation of the carbonyl oxygen in δ -lactones gave the corresponding cyclic dialkoxycarbenium ions in the *E,Z*-configuration in two examples for which the structure was established crystallographically.³⁹ The barrier to rotation about the C-O bond in simple acyclic dialkoxycarbenium ions has been estimated to be 11 $\pm$ 4 kcal.mol⁻¹ by VT-NMR spectroscopy.⁶²

The fundamental reaction step in the cyclization of an alkoxycarbonylmethyl ether onto an oxocarbenium ion, as required for participation in donors such as **11** and **13**, is illustrated for a simple model *trans*-ester leading to the formation of an *E,Z*-dialkoxycarbenium ion in Figure 2A. The basic reaction step for participation by a non-vicinal ester via a six-membered ring (such as from the 3-position of a glycosyl oxocarbenium ion) resulting in the formation of *Z,Z*-configured dialkoxycarbenium ion is illustrated by the simple model methoxyacetate ester presented in Figure 2B. DFT calculations conducted by the B3LYP method in the gas phase with the 6-31+G(d,p) basis set using the Gaussian09W suite of programs^{65–69} indicate a small ΔG of 1.74 kcal.mol⁻¹ between the two homodesmotic possibilities of Figure 1 with the cyclization of the 2-*O*-(alkoxycarbonylmethyl) ether resulting in the *E,Z*-dialkoxycarbenium ion being the more favoured of the two. Therefore, other factors being equal, there is no reason to expect that non-vicinal participation by a 3-*O*-ester via a six-membered ring intermediate will be intrinsically more favourable than that of the 2-*O*-alkoxycarbonylmethyl ethers investigated here. Overall the results argue that, consistent with earlier work from our laboratory and in the absence of conformational predisposition as with axial esters at the 3-position,⁴⁷ effective stereodirecting participation

by non-vicinal esters through the formation of six-membered intermediates is unlikely to be a serious contributing factor in glycosylation.

Boons and coworkers have described the influence of the 2-*O*-(ethoxycarbonylbenzyl) protecting group on the stereoselectivity of glucopyranosylation reactions with particular emphasis on participation and the role of the stereogenic center at the benzylic position.^{70–71} Thus, the *S*-configured donors **29** were found to afford α -glucosides **30** selectively, while the *R*-configured diastereomers **31** gave the β -glucosides **32** selectively (Scheme 4). These results were rationalized in terms of participation by the ethoxycarbonylbenzyl group with preferential formation of *trans*- and *cis*-decalin-like intermediates **33** and **34** for the *S*- and *R*-series, respectively, so as to accommodate the phenyl group in an equatorial position (Scheme 4). Computations were advanced in support of this hypothesis.⁷¹ In the *S*-series the use of an ester protecting group for O3 (**29**, R = Ac, Bz or Alloc) was essential for α -selectivity as ether protection at that position (**29**, R = allyl) gave less selective and even β -selective glucosylation depending on the acceptor employed. In the *R*-series the dependence of selectivity on the 3-*O*-protecting group was less marked (**31**, R = Allyl, Ac, Bz or Alloc).^{70–71}

The apparent conflict between the clear absence of participation in the glycosylation reactions of donors **11–13** and the bridging intermediates **33** and **34** advanced^{70–71} in explanation of the selectivities observed with donors **29** and **31**, respectively, may be reconciled in either of two ways. Thus, it is possible that the additional phenyl substituent in **29** and **31** promotes cyclization through conformational restriction in the manner of a Thorpe-Ingold or gem-dimethyl effect.⁷² Alternatively, it is possible that **33** and **34** are not intermediates in the stereodetermining step in the glycosylation reactions of **29** and **31**, which is simply the result of differential shielding of the two faces of transient oxocarbenium ions formed on activation according to the chirality of the protecting group at the 2-position. In support of this latter hypothesis Kumar and Whitfield have presented evidence for influence of protecting group chirality in the anomeric selectivity of glycosylation reactions conducted with the non-participating 2-*O*-(1-cyclopropylethyl)-protected series of donors **35**.⁷³ We are unable to distinguish between the two possibilities on the basis of the data available.

Conclusion

The formation and isolation of cyclic products on employment of the 2-*O*-phenacyl ether in mannopyranosylation establishes that participation by the 2-*O*-(2-oxoalkyl) ether system through a six-membered cyclic intermediate is stereoelectronically feasible. Such participation is diminished when the phenacyl group carries strongly electron-withdrawing substituents. The absence of cyclic products and the high β -selectivities observed excludes participation by the ester function of 2-*O*-(methoxycarbonylmethyl) ethers in mannopyranosylation and argues against participation by simple esters at the 3-position of glycosyl donors. The selective deprotection of the 2-*O*-(bistrifluoromethyl)phenacyl and 2-*O*-(methoxycarbonylmethyl) ethers extends the possible use of these systems beyond that of simple mechanistic probes to potentially useful protecting groups in glycosylation reactions.

Experimental Section

General Experimental

All reactions were performed using oven-dried glassware under an atmosphere of argon. All reagents and solvents were purchased from commercial suppliers and were used without further purification unless otherwise specified. Chromatographic purifications were performed on silica gel (230–400 mesh) columns. Reactions were monitored by analytical thin-layer chromatography on pre-coated glass backed plates (w/UV 254) and visualized by UV irradiation (254 nm) or by staining with 25% H_2SO_4 in EtOH or ceric ammonium molybdate solution. Specific rotations were measured on an automatic polarimeter with a path length of 100 mm in the solvent specified. Concentrations are given in g/100 mL. High resolution mass spectra (HRMS) were recorded with an electrospray ionization (ESI) source coupled to a time-of-flight (TOF) mass analyzer or with an electron impact (EI) source coupled to a TOF mass analyzer. ^1H , ^{13}C , ^{19}F , spectra were recorded on a 400, 500 or 600 MHz spectrometer. NMR solvents were used without purification. Chemical shifts are given in ppm (δ) and coupling constants (J) are given in Hz. Multiplicities are given as singlet (s), broad singlet (br s), doublet (d), triplet (t), doublet of doublets (dd), triplet of doublets (td), septuplet (sept), or multiplet (m).

2-[2',4'-Bis(trifluoromethyl)phenyl]propene—A solution of 1-[2,4-bis(trifluoromethyl)phenyl]ethanone (50 mg, 0.20 mmol) in diethyl ether (0.5 mL) was added dropwise into a stirred solution of methylmagnesium iodide in diethyl ether (1 M, 1 mL, 1 mmol) under argon at rt. After stirring at rt for 40 min, the reaction was quenched by adding 3 N HCl (1 mL) slowly. The resulting mixture was extracted with diethyl ether, the combined organic layers was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. Chromatographic purification (10% ethyl acetate/hexanes) afforded 2-[2',4'-bis(trifluoromethyl)phenyl]propan-2-ol as a colorless oil (42 mg, 79%): ¹H NMR (400 MHz, CDCl₃) δ 8.03 – 8.00 (m, 1H), 7.83 – 7.71 (m, 2H), 1.71 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 152.3, 129.4 (q, *J* = 33.5 Hz), 129.0, 128.3, 127.9 (q, *J* = 31.9 Hz), 125.3 – 124.9 (m), 124.0 (q, *J* = 273.5 Hz), 123.4 (q, *J* = 272.0 Hz), 73.6, 32.3. ¹⁹F NMR (376 MHz, CDCl₃) δ –54.66, –63.01. To a solution of 2-[2',4'-bis(trifluoromethyl)phenyl]propan-2-ol (42 mg, 0.15 mmol) in benzene (1.5 mL) was added *p*-toluenesulfonic acid monohydrate (2.9 mg, 0.015 mmol) at rt. The mixture was then refluxed for 12 h before cooling to rt and concentration under reduced pressure. Chromatographic purification (hexanes) afforded the title compound as a colorless oil (30 mg, 76%): ¹H NMR (400 MHz, CDCl₃) δ 7.90 (s, 1H), 7.75 (d, *J* = 8.0 Hz, 1H), 7.40 (d, *J* = 8.0 Hz, 1H), 5.32 – 5.28 (m, 1H), 4.93 (s, 1H), 2.09 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 147.1, 142.1, 130.8, 129.5 (q, *J* = 33.2 Hz), 128.6 (q, *J* = 31.0 Hz), 128.2 (d, *J* = 3.9 Hz), 123.4 (q, *J* = 274.6 Hz, 2*CF₃), 123.5 – 123.1 (m), 117.0, 24.8. ¹⁹F NMR (376 MHz, CDCl₃) δ –58.77, –62.86. HRMS (EI-TOF) *m/z*: Calcd. for C₁₁H₈F₆ ([M]⁺): 254.0530; found: 254.0543.

1-(3-Bromoprop-1-en-2-yl)-2,4-bis(trifluoromethyl)benzene—A solution of 2-[2',4'-bis(trifluoromethyl)phenyl]propene (84 mg, 0.33 mmol), *N*-bromosuccinimide (64 mg, 0.36 mmol) and azobisisobutyronitrile (5.4 mg, 0.03 mmol) in benzene (1.5 mL) was refluxed at 85 °C under argon for 2 h. After cooling to rt, the reaction mixture was concentrated under reduced pressure. Chromatographic purification (hexanes) afforded the title compound as a colorless oil (93 mg, 84%): ¹H NMR (400 MHz, CDCl₃) δ 7.94 (s, 1H), 7.81 (d, *J* = 8.1 Hz, 1H), 7.59 (d, *J* = 8.0 Hz, 1H), 5.73 (s, 1H), 5.24 (s, 1H), 4.24 (s, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 142.0, 132.9, 132.8, 130.6 (q, *J* = 33.6 Hz), 129.1 (q, *J* = 30.9 Hz), 128.2 (d, *J* = 4.0 Hz), 123.6 – 123.2 (m), 123.30 (q, *J* = 274.0 Hz), 123.25 (q, *J* = 272.2 Hz), 122.1, 35.5 (d, *J* = 2.8 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ –58.62, –62.97. HRMS (EI-TOF) *m/z*: Calcd. for C₁₁H₇F₆Br ([M]⁺): 331.9635; found: 331.9630 (1%), Calcd. for C₁₁H₇F₆ ([M - Br]⁺): 253.0452; found: 253.0447 (100%).

Phenyl 3-*O*-benzyl-4,6-*O*-benzylidene-2-*O*-(2-phenylprop-2-en-1-yl)-1-thio- α -D-mannopyranoside (2)—To a stirred solution of phenyl 3-*O*-benzyl-4,6-*O*-benzylidene-1-thio- α -D-mannopyranoside (500 mg, 1.1 mmol) in THF (1.5 mL) at 0 °C was added sodium hydride (58 mg, 60% suspension in mineral oil, 1.4 mmol). After stirring at 0 °C for 30 min, a solution of 3-bromoprop-1-en-2-yl-benzene (284 mg, 1.4 mmol) in THF (0.4 mL) was added dropwise. The resulting mixture was stirred at rt for 48 h. After completion, ethyl acetate was added, and the reaction mixture was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. Chromatographic purification (6% ethyl acetate/hexanes) afforded the title compound as a colorless oil (588 mg, 94%): [α]_D²¹ +124.2 (*c* 3.12, CH₂Cl₂). ¹H NMR (600 MHz, CDCl₃) δ 7.59 – 7.21 (m, 20H), 5.62 (s, 1H), 5.54 (s,

1H), 5.36 (d, $J = 1.2$ Hz, 2H), 5.32 (d, $J = 1.2$ Hz, 2H), 4.84 (d, $J = 12.1$ Hz, 1H), 4.72 – 4.63 (m, 2H), 4.57 (d, $J = 13.0$ Hz, 2H), 4.30 – 4.22 (m, 2H), 4.19 (dd, $J = 10.2, 3.9$ Hz, 1H), 4.09 (dd, $J = 3.2, 1.4$ Hz, 1H), 3.96 (dd, $J = 9.5, 3.2$ Hz, 1H), 3.85 (t, $J = 9.9$ Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 144.1, 138.41, 138.39, 137.6, 133.7, 131.9, 131.7, 129.1, 128.9, 128.6, 128.40, 128.37, 128.3, 128.2, 127.9, 127.73, 127.66, 127.6, 126.8, 126.3, 126.1, 115.6, 101.5, 101.4, 87.3, 79.2, 77.6, 76.4, 73.2, 68.5, 65.4. HRMS (ESI-TOF) m/z : Calcd. for $\text{C}_{35}\text{H}_{34}\text{O}_5\text{SNa}$ ($[\text{M} + \text{Na}]^+$): 589.2025; found: 589.2025.

Phenyl 3-*O*-benzyl-4,6-*O*-benzylidene-2-*O*-phenacyl-1-thio- α -D-mannopyranoside (5) and Phenyl 3-*O*-benzyl-4,6-*O*-benzylidene-2-*O*-phenacyl-1-thio- α -D-mannopyranoside S-oxide (8)— O_3 was bubbled into a stirred solution of **2** (268 mg, 0.47 mmol) in DCM (10 mL) at -78°C for 10 min until the appearance of a deep blue color. Ar was then bubbled through the solution for 15 min, before triphenylphosphine (373 mg, 1.42 mmol) was added and the reaction mixture was allowed to warm to rt. After stirring at rt for a further 3 h, the mixture was concentrated. Chromatographic purification (14% ethyl acetate/hexanes) afforded the desired ketone product as a colorless oil (161 mg, 60%) $[\alpha]_{\text{D}}^{21} +102.2$ (c 0.7, CH_2Cl_2). ^1H NMR (600 MHz, CDCl_3) δ 7.86 – 7.82 (m, 2H), 7.59 – 7.55 (m, 1H), 7.53 – 7.25 (m, 17H), 5.99 (d, $J = 1.4$ Hz, 1H), 5.64 (s, 1H), 5.14 – 5.04 (m, 2H), 4.92 (d, $J = 12.0$ Hz, 1H), 4.70 (d, $J = 11.9$ Hz, 1H), 4.36 – 4.29 (m, 2H), 4.23 (dd, $J = 10.3, 3.8$ Hz, 1H), 4.08 (dd, $J = 3.0, 1.4$ Hz, 1H), 4.00 (dd, $J = 9.6, 2.9$ Hz, 1H), 3.91 – 3.87 (m, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 196.5, 138.2, 137.5, 134.7, 133.59, 133.55, 131.5, 129.1, 128.9, 128.7, 128.4, 128.2, 127.81, 127.77, 127.7, 127.5, 126.1, 101.5, 87.9, 80.1, 79.4, 74.9, 73.7, 68.5, 65.3. HRMS (ESI-TOF) m/z : Calcd. for $\text{C}_{34}\text{H}_{32}\text{O}_6\text{SNa}$ ($[\text{M} + \text{Na}]^+$): 591.1817; found: 591.1790. Further elution (20% ethyl acetate/hexanes) gave the sulfoxide as a colorless oil (51 mg, 18%): $[\alpha]_{\text{D}}^{21} -26.4$ (c 1.48, CHCl_3). ^1H NMR (600 MHz, CDCl_3) δ 7.75 – 7.70 (m, 2H), 7.63 (dd, $J = 7.6, 1.9$ Hz, 2H), 7.57 – 7.47 (m, 6H), 7.43 – 7.34 (m, 7H), 7.33 – 7.26 (m, 3H), 5.63 (s, 1H), 5.10 (d, $J = 1.3$ Hz, 1H), 5.08 (d, $J = 17.4$ Hz, 1H), 4.96 (d, $J = 11.8$ Hz, 1H), 4.88 (d, $J = 17.1$ Hz, 1H), 4.75 (d, $J = 11.8$ Hz, 1H), 4.38 – 4.32 (m, 2H), 4.31 (s, 1H), 4.26 (dd, $J = 10.4, 4.9$ Hz, 1H), 4.18 (td, $J = 9.5, 4.8$ Hz, 1H), 3.79 (t, $J = 10.2$ Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 195.6, 141.4, 138.2, 137.2, 134.5, 133.5, 131.6, 129.4, 129.0, 128.6, 128.4, 128.3, 127.9, 127.8, 127.7, 126.1, 124.5, 101.7, 98.2, 78.3, 77.1, 75.8, 75.2, 74.0, 69.9, 68.3. HRMS (ESI-TOF) m/z : Calcd. for $\text{C}_{34}\text{H}_{32}\text{O}_7\text{SNa}$ ($[\text{M} + \text{Na}]^+$): 607.1766; found: 607.1765.

Compound **8** was also prepared by *m*CPBA oxidation of **5**: To a stirred solution of **5** (104 mg, 0.18 mmol) in DCM (2 mL) at -78°C under an argon atmosphere was added a solution of *m*CPBA (77%, 40.9 mg, 0.18 mmol) in DCM (1 mL) dropwise. After stirring at this temperature for 3 h, saturated NaHCO_3 solution (1 mL) was added and the mixture was then allowed to warm to rt. DCM (10 mL) was added and the separated organic layer was washed with saturated aqueous NaHCO_3 , brine, dried over Na_2SO_4 and concentrated under reduced pressure. Chromatographic purification (20% ethyl acetate/hexanes) afforded **8** (64.2 mg, 60%) which was identical to the above sample.

Phenyl 3-*O*-benzyl-4,6-*O*-benzylidene-2-*O*-[2-(4'-trifluoromethyl)phenylprop-2-en-1-yl]-1-thio- α -D-mannopyranoside (3)—To a stirred solution of 3-*O*-benzyl-4,6-

O-benzylidene-1-thio- α -D-mannopyranoside (100 mg, 0.22 mmol) in THF (0.5 mL) at 0 °C was added sodium hydride (13.3 mg, 60% suspension in mineral oil, 0.33 mmol). After stirring at 0 °C for 20 min, a solution of 1-(3-bromoprop-1-en-2-yl)-4-(trifluoromethyl)benzene¹ (88.2 mg, 0.33 mmol) in THF (1.5 mL) was added dropwise. The resulting mixture was stirred at rt for 48 h. After the completion of reaction, ethyl acetate was added, then it was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. Chromatographic purification (6% ethyl acetate/hexanes) afforded the title compound as a colorless oil (109 mg, 78%): $[\alpha]_D^{21} +94.6$ (*c* 0.95, CHCl₃). ¹H NMR (500 MHz, CDCl₃) δ 7.61 (d, *J* = 8.1 Hz, 2H), 7.57 – 7.48 (m, 4H), 7.44 – 7.28 (m, 13H), 5.65 (s, 1H), 5.64 (s, 1H), 5.48 (s, 1H), 5.36 (d, *J* = 1.3 Hz, 1H), 4.91 (d, *J* = 11.9 Hz, 1H), 4.70 (d, *J* = 11.9 Hz, 1H), 4.66 (d, *J* = 12.5 Hz, 1H), 4.58 (d, *J* = 12.6 Hz, 1H), 4.34 – 4.25 (m, 2H), 4.23 (dd, *J* = 10.3, 4.5 Hz, 1H), 4.11 (dd, *J* = 3.3, 1.4 Hz, 1H), 4.02 (dd, *J* = 9.3, 3.2 Hz, 1H), 3.87 (t, *J* = 9.9 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 143.0, 142.0, 138.3, 137.5, 133.6, 131.7, 129.8 (q, *J* = 32.3 Hz), 129.2, 128.9, 128.4, 128.2, 127.79, 127.76 (2 carbons), 126.7, 126.1, 125.3 (q, *J* = 3.9 Hz), 124.2 (q, *J* = 272.0 Hz), 117.8, 101.5, 87.2, 79.3, 78.0, 76.4, 73.5, 73.2, 68.5, 65.4. ¹⁹F NMR (376 MHz, CDCl₃) δ –62.51. HRMS (ESI-TOF) *m/z*: Calcd. for C₃₆H₃₃F₃O₅SNa ([M + Na]⁺): 657.1898; found: 657.1901.

Phenyl 3-*O*-benzyl-4,6-*O*-benzylidene-2-*O*-(4'-trifluoromethylphenacyl)-1-thio- α -D-mannopyranoside (6) and Phenyl 3-*O*-benzyl-4,6-*O*-benzylidene-2-*O*-(4'-trifluoromethylphenacyl)-1-thio- α -D-mannopyranoside *S*-oxide (9)—O₃ was bubbled into a stirred solution of **3** (100 mg, 0.16 mmol) in DCM (4 mL) and methanol (1 mL) at –78 °C for 5 min until the appearance of a deep blue color. Ar was then bubbled through the solution for 15 min, before triphenylphosphine (124 mg, 0.47 mmol) was added and the reaction mixture was allowed to warm to rt. After stirring at rt for a further 3 h, the mixture was concentrated. Chromatographic purification (14% ethyl acetate/hexanes) afforded the desired ketone product as a colorless oil (78 mg, 77%): $[\alpha]_D^{21} +72.7$ (*c* 1.245, CHCl₃). ¹H NMR (500 MHz, CDCl₃) δ 7.97 (d, *J* = 8.1 Hz, 2H), 7.68 (d, *J* = 8.2 Hz, 2H), 7.56 – 7.46 (m, 4H), 7.44 – 7.28 (m, 11H), 5.91 (d, *J* = 1.4 Hz, 1H), 5.64 (s, 1H), 5.10 – 5.00 (m, 2H), 4.94 (d, *J* = 11.7 Hz, 1H), 4.70 (d, *J* = 11.8 Hz, 1H), 4.36 (td, *J* = 9.6, 4.7 Hz, 1H), 4.30 (t, *J* = 9.5 Hz, 1H), 4.26 (dd, *J* = 10.3, 4.7 Hz, 1H), 4.10 (dd, *J* = 3.0, 1.5 Hz, 1H), 4.04 (dd, *J* = 9.5, 3.0 Hz, 1H), 3.89 (t, *J* = 10.1 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 195.7, 138.1, 137.5, 137.4, 134.7 (q, *J* = 32.7 Hz), 133.5, 131.6, 129.2, 129.0, 128.5, 128.4, 128.2, 127.9, 127.8, 127.7, 126.1, 125.7 (q, *J* = 3.9 Hz), 123.5 (q, *J* = 272.7 Hz), 101.6, 87.8, 80.4, 79.5, 77.0, 75.2, 74.0, 68.5, 65.3. ¹⁹F NMR (376 MHz, CDCl₃) δ –63.19. HRMS (ESI-TOF) *m/z*: Calcd. for C₃₅H₃₁F₃O₆SNa ([M + Na]⁺): 659.1691; found: 659.1662. Further elution (20% ethyl acetate/hexanes) gave the sulfoxide as a colorless oil (19 mg, 18%): $[\alpha]_D^{21} -10.4$ (*c* 0.94, CHCl₃). ¹H NMR (600 MHz, CDCl₃) δ 7.85 – 7.81 (m, 2H), 7.63 (dd, *J* = 7.6, 1.8 Hz, 4H), 7.57 – 7.52 (m, 3H), 7.49 (dd, *J* = 7.7, 1.9 Hz, 2H), 7.41 – 7.33 (m, 5H), 7.32 – 7.26 (m, 3H), 5.62 (s, 1H), 5.03 (d, *J* = 16.9 Hz, 1H), 4.97 (s, 1H), 4.96 (d, *J* = 11.8 Hz, 1H), 4.84 (d, *J* = 16.9 Hz, 1H), 4.72 (d, *J* = 11.6 Hz, 1H), 4.33 (m, 3H), 4.25 (dd, *J* = 10.4, 4.9 Hz, 1H), 4.15 (td, *J* = 9.5, 4.9 Hz, 1H), 3.77 (t, *J* = 10.2 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 194.9, 141.5, 138.1, 137.2, 137.1, 134.7 (q, *J* = 32.8 Hz), 131.7, 129.4, 129.1, 128.4, 128.27, 128.26, 128.0, 127.9, 126.0, 125.6 (q, *J* = 3.7 Hz), 124.5, 123.4 (q, *J* = 272.7 Hz), 101.7, 98.1, 78.4, 77.1, 75.9, 75.5, 74.3, 69.9, 68.2. ¹⁹F NMR (376 MHz, CDCl₃)

δ –63.21. HRMS (ESI-TOF) m/z : Calcd. for $C_{35}H_{31}F_3O_7SNa$ ($[M + Na]^+$): 675.1640; found: 675.1640.

Compound **9** was also prepared by *m*CPBA oxidation of **6**: To a stirred solution of **6** (37 mg, 0.06 mmol) in DCM (0.8 mL) at -78°C under argon atmosphere was added a solution of *m*CPBA (77%, 13.1 mg, 0.06 mmol) in DCM (0.4 mL) dropwise. After stirring at this temperature for 4 h, saturated NaHCO_3 solution (1 mL) was added and the mixture was then allowed to warm to rt. DCM (10 mL) was added and the separated organic layer was washed with saturated aqueous NaHCO_3 , brine, dried over Na_2SO_4 and concentrated under reduced pressure. Chromatographic purification (20% ethyl acetate/hexanes) afforded **9** (31.6 mg, 83%) which was identical to the above sample.

Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-[2-(2',4'-bis-trifluoromethyl)phenylprop-2-en-1-yl]-1-thio- α -D-mannopyranoside (4)—To a solution of 3-O-benzyl-4,6-O-benzylidene-1-thio- α -D-mannopyranoside (100 mg, 0.22 mmol) and tetrabutylammonium iodide (4.1 mg, 0.01 mmol) in DMF (0.8 mL) was added sodium hydride (13.4 mg, 60% suspension in mineral oil, 0.33 mmol) at 0°C . After stirring at this temperature for 30 min, a solution of 1-(3-bromoprop-1-en-2-yl)-2,4-bis(trifluoromethyl)benzene (97 mg, 0.29 mmol) in DMF (0.7 mL) was added dropwise. After that, the reaction mixture was stirred at rt for 6 h before it was diluted with ethyl acetate, washed with brine, dried over Na_2SO_4 and concentrated under reduced pressure. Chromatographic purification (6% ethyl acetate/hexanes) afforded the title compound as a colorless oil (140 mg, 89%): $[\alpha]_D^{21} +80.5$ (c 1.225, CH_2Cl_2). ^1H NMR (500 MHz, CDCl_3) δ 7.93 (d, J = 1.7 Hz, 1H), 7.61 – 7.53 (m, 3H), 7.53 – 7.29 (m, 14H), 5.72 (d, J = 1.5 Hz, 1H), 5.68 (s, 1H), 5.51 (d, J = 1.3 Hz, 1H), 5.22 (s, 1H), 4.94 (d, J = 11.8 Hz, 1H), 4.73 (d, J = 11.9 Hz, 1H), 4.40 (m, 2H), 4.35 (td, J = 9.7, 5.1 Hz, 1H), 4.29 (t, J = 10.0 Hz, 1H), 4.28 (dd, J = 10.2, 5.0 Hz, 1H), 4.10 (dd, J = 3.1, 1.4 Hz, 1H), 4.05 (dd, J = 9.7, 3.1 Hz, 1H), 3.90 (t, J = 10.1 Hz, 1H). ^{13}C NMR (126 MHz, CDCl_3) δ 143.0, 142.0, 138.2, 137.5, 133.6, 132.3, 131.8, 130.0 (q, J = 33.4 Hz), 129.3 (q, J = 30.7 Hz), 129.2, 129.0, 128.4, 128.3, 128.0 (d, J = 3.6 Hz), 127.89, 127.85, 127.8, 126.1, 123.43 (q, J = 274.1 Hz), 123.37 (q, J = 272.4 Hz), 123.4 – 123.0 (m), 118.8, 101.6, 87.0, 79.4, 79.3, 76.3, 74.0, 73.6, 68.6, 65.4. ^{19}F NMR (376 MHz, CDCl_3) δ –58.22, –62.81. HRMS (ESI-TOF) m/z : Calcd. for $C_{37}H_{32}F_6O_5SNa$ ($[M + Na]^+$): 725.1772; found: 725.1763.

Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-(2',4'-bis-trifluoromethylphenacyl)-1-thio- α -D-mannopyranoside (7) and Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-(2',4'-bis-trifluoromethylphenacyl)-1-thio- α -D-mannopyranoside S-oxide (10)— O_3 was bubbled into a stirred solution of **4** (124 mg, 0.18 mmol) in DCM (4 mL) and methanol (1 mL) at -78°C for 15 min until the appearance of a deep blue color. Ar was then bubbled through the solution for 15 min, before triphenylphosphine (139 mg, 0.53 mmol) was added and the reaction mixture was allowed to warm to rt. After stirring at rt for a further 1 h, the mixture was concentrated. Chromatographic purification (14% ethyl acetate/hexanes) afforded the desired ketone product as a colorless oil (25 mg, 20%): $[\alpha]_D^{21} +108.1$ (c 0.67, CHCl_3). ^1H NMR (400 MHz, CDCl_3) δ 7.95 (s, 1H), 7.76 – 7.71 (m, 1H), 7.54 – 7.27 (m, 16H), 5.71 (d, J = 1.5 Hz,

1H), 5.60 (s, 1H), 4.92 (d, $J = 11.7$ Hz, 1H), 4.83 (s, 2H), 4.69 (d, $J = 11.7$ Hz, 1H), 4.31 (td, $J = 9.7, 4.8$ Hz, 1H), 4.23 (dd, $J = 10.6, 5.1$ Hz, 1H), 4.18 (t, $J = 9.7$ Hz, 1H), 4.09 (dd, $J = 3.0, 1.5$ Hz, 1H), 4.02 (dd, $J = 9.8, 2.9$ Hz, 1H), 3.83 (t, $J = 10.2$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 200.3, 140.4, 138.1, 137.4, 133.2, 132.7 (q, $J = 33.8$ Hz), 131.8, 129.2, 129.0, 128.62, 128.60 (q, $J = 32.9$ Hz), 128.5, 128.4, 128.2, 127.92, 127.90, 127.8, 126.0, 124.0 – 123.8 (m), 122.8 (q, $J = 272.5$ Hz), 122.7 (q, $J = 274.5$ Hz), 101.6, 88.0, 80.4, 79.6, 77.0, 76.7, 74.1, 68.5, 65.3. ^{19}F NMR (376 MHz, CDCl_3) δ –58.27, –63.17. HRMS (ESI-TOF) m/z : Calcd. for $\text{C}_{36}\text{H}_{30}\text{F}_6\text{O}_6\text{SNa}$ ($[\text{M} + \text{Na}]^+$): 727.1565; found: 727.1570. As well as sulfoxide product Further elution (20% ethyl acetate/hexanes) gave the sulfoxide as a colorless oil (69 mg, 54%): $[\alpha]_{\text{D}}^{21} -36.4$ (c 0.963, CHCl_3). ^1H NMR (500 MHz, CDCl_3) δ 7.93 (d, $J = 1.6$ Hz, 1H), 7.73 (dd, $J = 8.0, 1.6$ Hz, 1H), 7.65 – 7.47 (m, 7H), 7.45 – 7.23 (m, 9H), 5.61 (s, 1H), 4.97 (d, $J = 11.6$ Hz, 1H), 4.84 (d, $J = 17.0$ Hz, 1H), 4.82 (s, 1H), 4.74 (d, $J = 11.5$ Hz, 1H), 4.67 (d, $J = 18.4$ Hz, 1H), 4.38 (dd, $J = 9.7, 3.2$ Hz, 1H), 4.34 (dd, $J = 3.3, 1.4$ Hz, 1H), 4.27 (dd, $J = 9.8, 4.2$ Hz, 1H), 4.24 (t, $J = 9.0$ Hz, 1H), 4.18 (td, $J = 9.5, 4.7$ Hz, 1H), 3.75 (t, $J = 10.0$ Hz, 1H). ^{13}C NMR (126 MHz, CDCl_3) δ 199.8, 141.2, 140.2, 138.1, 137.1, 132.7 (q, $J = 33.9$ Hz), 131.8, 129.5, 129.1, 128.63 (d, $J = 3.8$ Hz), 128.57 (q, $J = 33.4$ Hz), 128.5, 128.33, 128.30, 128.1, 128.0, 126.0, 124.4, 124.0 – 123.7 (m), 122.7 (q, $J = 264.5$ Hz), 122.6 (q, $J = 274.2$ Hz), 101.7, 98.2, 78.5, 77.6, 77.1, 75.6, 74.4, 69.9, 68.2. ^{19}F NMR (376 MHz, CDCl_3) δ –58.32, –63.16. HRMS (ESI-TOF) m/z : Calcd. for $\text{C}_{36}\text{H}_{30}\text{F}_6\text{O}_7\text{SNa}$ ($[\text{M} + \text{Na}]^+$): 743.1514; found: 743.1486.

Compound **10** was also prepared by *m*CPBA oxidation of **7**: To a stirred solution of **7** (46 mg, 0.07 mmol) in DCM (1 mL) at -78°C under argon atmosphere was added a solution of *m*CPBA (77%, 14.6 mg, 0.07 mmol) in DCM (0.5 mL) dropwise. After stirring at this temperature for 4 h, saturated NaHCO_3 solution (1 mL) was added and the mixture was then allowed to warm to rt. DCM (10 mL) was added and the separated organic layer was washed with saturated NaHCO_3 solution once, brine, dried over Na_2SO_4 and concentrated under reduced pressure. Chromatographic purification (20% ethyl acetate/hexanes) afforded **10** (39 mg, 83%) which was identical to the above sample.

Phenyl 3-*O*-benzyl-4,6-*O*-benzylidene-2-*O*-(methoxycarbonylmethyl)-1-thio- α -D-mannopyranoside (11**)**—To a stirred solution of 3-*O*-benzyl-4,6-*O*-benzylidene-1-thio- α -D-mannopyranoside (100 mg, 0.22 mmol) in THF (0.8 mL) at 0°C was added sodium hydride (13.3 mg, 60% suspension in mineral oil, 0.33 mmol). After stirring at 0°C for 25 min, a solution of methyl bromoacetate (51 mg, 0.33 mmol) in THF (0.2 mL) was added dropwise. The resulting mixture was stirred at rt for 5 h. After the completion of reaction, ethyl acetate was added, then it was washed with brine, dried over Na_2SO_4 and concentrated under reduced pressure. Chromatographic purification (14% ethyl acetate/hexanes) afforded the title compound as a colorless oil (89 mg, 78%): $[\alpha]_{\text{D}}^{21} +167.7$ (c 1, CHCl_3). ^1H NMR (500 MHz, CDCl_3) δ 7.53 (dd, $J = 7.7, 1.9$ Hz, 2H), 7.50 – 7.46 (m, 2H), 7.35 (m, 1H), 5.86 (d, $J = 1.5$ Hz, 1H), 5.67 (s, 1H), 4.94 (d, $J = 12.0$ Hz, 1H), 4.75 (d, $J = 12.0$ Hz, 1H), 4.49 – 4.38 (m, 2H), 4.36 – 4.29 (m, 2H), 4.25 (dd, $J = 10.3, 3.8$ Hz, 1H), 4.09 (dd, $J = 3.0, 1.5$ Hz, 1H), 4.01 (dd, $J = 9.6, 3.0$ Hz, 1H), 3.91 (t, $J = 9.9$ Hz, 1H), 3.72 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 171.0, 138.2, 137.5, 133.6, 131.6, 129.2, 128.9, 128.5, 128.2, 127.8, 127.7, 127.6, 126.1, 101.5, 88.0, 80.4, 79.4, 77.31, 77.25, 77.1, 76.8, 76.7,

73.7, 69.4, 68.5, 65.3, 51.9. HRMS (ESI-TOF) m/z : Calcd. for $C_{29}H_{30}O_7SNa$ ($[M + Na]^+$): 545.1610; found: 545.1622.

Phenyl 3-*O*-benzyl-4,6-*O*-benzylidene-2-*O*-(*t*-butoxycarbonylmethyl)-1-thio- α -D-mannopyranoside (12**)**—To a stirred solution of 3-*O*-benzyl-4,6-*O*-benzylidene-1-thio- α -D-mannopyranoside (100 mg, 0.22 mmol) in THF (1.0 mL) at 0 °C was added sodium hydride (13.3 mg, 60% suspension in mineral oil, 0.33 mmol). After stirring at 0 °C for 20 min, a solution of *tert*-butyl bromoacetate (65.0 mg, 0.33 mmol) in THF (0.4 mL) was added dropwise. The resulting mixture was stirred at rt for 5 h. After the completion of reaction, ethyl acetate was added, and the reaction mixture was washed with brine, dried over Na_2SO_4 and concentrated under reduced pressure. Chromatographic purification (8% ethyl acetate/hexanes) afforded the title compound as a colorless oil (75 mg, 60%): $[\alpha]_D^{21} +140.3$ (c 1.21, $CHCl_3$). 1H NMR (600 MHz, $CDCl_3$) δ 7.52 – 7.49 (m, 2H), 7.47 – 7.43 (m, 2H), 7.41 – 7.33 (m, 7H), 7.32 – 7.23 (m, 4H), 5.86 (d, J = 1.4 Hz, 1H), 5.64 (s, 1H), 4.92 (d, J = 12.0 Hz, 1H), 4.73 (d, J = 12.1 Hz, 1H), 4.33 – 4.25 (m, 4H), 4.24 – 4.21 (m, 1H), 4.03 (dd, J = 3.0, 1.5 Hz, 1H), 3.99 – 3.97 (m, 1H), 3.92 – 3.87 (m, 1H), 1.43 (s, 9H). ^{13}C NMR (151 MHz, $CDCl_3$) δ 169.7, 138.3, 137.5, 133.7, 131.3, 129.1, 128.9, 128.4, 128.2, 127.72, 127.67, 127.5, 126.0, 101.5, 87.9, 81.8, 80.1, 79.4, 76.7, 73.6, 70.2, 68.5, 65.2, 28.1. HRMS (ESI-TOF) m/z : Calcd. for $C_{32}H_{36}O_7SNa$ ($[M + Na]^+$): 587.2079; found: 587.2083.

Phenyl 3-*O*-benzyl-4,6-*O*-benzylidene-2-*O*-(methoxycarbonylmethyl)-1-thio- α -D-mannopyranoside *S*-oxide (13**) and Phenyl 3-*O*-benzyl-4,6-*O*-benzylidene-2-*O*-(methoxycarbonylmethyl)-1-thio- α -D-mannopyranoside sulfone (**15**)**—To a stirred solution of **11** (104 mg, 0.20 mmol) in DCM (2 mL) at –78 °C under argon atmosphere was added a solution of *m*CPBA (77%, 44.4 mg, 0.20 mmol) in DCM (2 mL) dropwise. After stirring at this temperature for 6 h, saturated $NaHCO_3$ solution (1 mL) was added and the mixture was then allowed to warm to rt. DCM (10 mL) was added and the separated organic layer was washed with saturated aqueous $NaHCO_3$, brine, dried over Na_2SO_4 and concentrated under reduced pressure. Chromatographic purification (33% ethyl acetate/hexanes) afforded the sulfoxide product as a colorless oil (70.2 mg, 66%). $[\alpha]_D^{21} -4.8$ (c 0.15, $CHCl_3$). 1H NMR (500 MHz, $CDCl_3$) δ 7.67 – 7.60 (m, 2H), 7.57 (dt, J = 4.7, 2.9 Hz, 3H), 7.54 – 7.48 (m, 2H), 7.45 – 7.30 (m, 8H), 5.65 (s, 1H), 4.97 (s, 1H), 4.96 (d, J = 10.7 Hz, 1H), 4.78 (d, J = 11.9 Hz, 1H), 4.40 (d, J = 16.9 Hz, 1H), 4.38 – 4.31 (m, 3H), 4.28 (d, J = 16.9 Hz, 1H), 4.27 (dd, J = 10.3, 4.9 Hz, 2H), 4.15 (td, J = 8.6, 7.5, 4.6 Hz, 1H), 3.80 (t, J = 10.2 Hz, 1H), 3.62 (s, 3H). ^{13}C NMR (126 MHz, $CDCl_3$) δ 170.6, 141.7, 138.1, 137.2, 131.7, 129.4, 129.0, 128.5, 128.3, 127.84, 127.81, 126.0, 124.5, 101.7, 98.2, 78.3, 76.7, 75.4, 74.0, 70.1, 69.9, 68.2, 51.8. HRMS (ESI-TOF) m/z : Calcd. for $C_{29}H_{30}O_8SNa$ ($[M + Na]^+$): 561.1559; found: 561.1550. The sulfone **15** (20% ethyl acetate/hexanes) was also isolated as a colorless oil (35.4 mg, 32%): $[\alpha]_D^{21} +81.5$ (c 0.15, $CHCl_3$). 1H NMR (500 MHz, $CDCl_3$) δ 7.97 – 7.90 (m, 2H), 7.75 – 7.68 (m, 1H), 7.61 (t, J = 7.9 Hz, 2H), 7.54 – 7.47 (m, 2H), 7.43 – 7.29 (m, 8H), 5.62 (s, 1H), 5.33 (s, 1H), 4.97 (d, J = 11.7 Hz, 1H), 4.77 (d, J = 11.7 Hz, 1H), 4.63 – 4.53 (m, 2H), 4.48 (d, J = 17.1 Hz, 1H), 4.44 (dd, J = 10.1, 3.4 Hz, 1H), 4.39 (d, J = 17.1 Hz, 1H), 4.27 (t, J = 9.8 Hz, 1H), 4.15 (dd, J = 10.3, 4.9 Hz, 1H), 3.73 (s, 3H), 3.69 (t, J = 10.3 Hz, 1H). ^{13}C NMR (126 MHz, $CDCl_3$) δ 170.9, 138.1, 137.3, 136.5, 134.4, 129.3, 129.0, 128.9, 128.5, 128.3, 127.88, 127.86, 126.1, 101.7, 93.6, 78.1

77.0, 74.8, 74.3, 70.6, 68.5, 68.4, 52.0. HRMS (ESI-TOF) m/z : Calcd. for $C_{29}H_{30}O_9SNa$ ($[M + Na]^+$): 577.1508; found: 577.1510.

Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-(*t*-butoxycarbonylmethyl)-1-thio- α -D-mannopyranoside S-oxide (14)—To a stirred solution of **12** (47 mg, 0.08 mmol) in DCM (1 mL) at -78°C under argon atmosphere was added a solution of *m*CPBA (77%, 18.5 mg, 0.08 mmol) in DCM (0.5 mL) dropwise. After stirring at this temperature for 3 h, saturated NaHCO_3 solution (1 mL) was added and the mixture was then allowed to warm to rt. DCM (10 mL) was added and the separated organic layer was washed with saturated aqueous NaHCO_3 , brine, dried over Na_2SO_4 and concentrated under reduced pressure. Chromatographic purification (17% ethyl acetate/hexanes) afforded the sulfoxide product as a colorless oil (38.0 mg, 79%). $[\alpha]_D^{21} -9.0$ (c 1.26, CHCl_3). ^1H NMR (400 MHz, CDCl_3) δ 7.65–7.58 (m, 2H), 7.57–7.46 (m, 5H), 7.44–7.28 (m, 8H), 5.64 (s, 1H), 5.00 (d, $J = 1.3$ Hz, 1H), 4.94 (d, $J = 12.0$ Hz, 1H), 4.78 (d, $J = 12.0$ Hz, 1H), 4.38–4.28 (m, 3H), 4.27 (d, $J = 16.9$ Hz, 1H), 4.25 (dd, $J = 10.2, 4.9$ Hz, 1H), 4.20–4.13 (m, 1H), 4.12 (d, $J = 16.9$ Hz, 1H), 3.79 (t, $J = 10.1$ Hz, 1H), 1.40 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 169.3, 141.5, 138.2, 137.2, 131.5, 129.3, 129.0, 128.4, 128.2, 127.8, 127.7, 126.0, 124.5, 101.6, 98.1, 81.8, 78.3, 76.7, 75.4, 73.8, 70.8, 69.8, 68.2, 28.1. HRMS (ESI-TOF) m/z : Calcd. for $C_{32}H_{36}O_8SNa$ ($[M + Na]^+$): 603.2029; found: 603.2015.

General procedure I: glycosylation with thioglycosides

A mixture of glycosyl donor (1 equiv.), diphenylsulfoxide or 1-benzenesulfinyl piperidine (1.1 equiv.), tri-*tert*-butylpyrimidine (2 equiv.) and activated 3 Å molecular sieves (2 g per mmol of donor) was stirred in dry DCM (13.3 mL per 1 mmol of donor) for 1 h at rt before it was cooled to -78°C , then trifluoromethanesulfonic anhydride (1.1 equiv.) was added. After stirring at the same temperature for 10 min, a solution of acceptor (1.5 equiv.) in dry DCM (4.4 mL per 1 mmol of acceptor) was added dropwise. The resulting mixture was then stirred at -78°C for 3 h before quenching with sat. NaHCO_3 solution at the same temperature. After warming to rt, the mixture was filtered and the filtrate was extracted with DCM, the combined organic layers was washed with saturated aqueous NaHCO_3 , brine, dried over Na_2SO_4 and concentrated under reduced pressure. Chromatographic purification afforded the product.

General procedure II: glycosylation with sulfoxides

A mixture of glycosyl donor (1 equiv.), tri-*tert*-butylpyrimidine (2 equiv.) and activated 3 Å molecular sieves (2 g per mmol of donor) was stirred in dry DCM (13 mL per 1 mmol of donor) for 1 h at rt before it was cooled to -78°C , then trifluoromethanesulfonic anhydride (1.1 equiv.) was added. After stirring at the same temperature for 10 min, a solution of acceptor (1.5 equiv.) in dry DCM (4.4 mL per 1 mmol of acceptor) was added dropwise. The resulting mixture was then stirred at -78°C for 3 h before quenching with saturated aqueous NaHCO_3 . After warming to rt, the mixture was filtered and the filtrate was extracted with DCM, the combined organic layer was washed with saturated aqueous NaHCO_3 and brine, dried over Na_2SO_4 and concentrated under reduced pressure. Chromatographic purification afforded the product.

1-Adamantanyl 4,6-O-benzylidene-2-O-(2',4'-bis-trifluoromethylphenacyl)-3-O-benzyl- β -D-mannopyranoside (20 β)—20 β was obtained from **10** by following general procedure II, 10% ethyl acetate/hexanes, colorless oil (34.3 mg, 50%): $[\alpha]_D^{21}$ -31.0 (c 0.545, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.94 (s, 1H), 7.74 (d, J = 1.6 Hz, 2H), 7.51 – 7.45 (m, 2H), 7.42 – 7.27 (m, 8H), 5.53 (s, 1H), 5.01 – 4.84 (m, 2H), 4.83 – 4.71 (m, 3H), 4.25 (dd, J = 10.4, 4.8 Hz, 1H), 3.98 (t, J = 9.6 Hz, 1H), 3.87 (d, J = 3.1 Hz, 1H), 3.81 (t, J = 10.3 Hz, 1H), 3.64 (dd, J = 9.9, 3.1 Hz, 1H), 3.30 (td, J = 9.7, 4.8 Hz, 1H), 2.22 – 2.10 (m, 3H), 1.84 – 1.68 (m, 6H), 1.68 – 1.53 (m, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 200.4, 140.8, 138.3, 137.5, 132.3 (q, J = 33.8 Hz), 129.4, 128.9, 128.6 (q, J = 33.8 Hz), 128.32, 128.26, 128.20, 127.8, 127.6, 126.0, 123.9 – 123.5 (m), 122.94 (q, J = 271.6 Hz), 122.87 (q, J = 274.2 Hz), 101.4, 94.8, 80.0, 78.4, 77.6, 77.4, 75.8, 72.6, 68.8, 67.2, 42.3, 36.1, 30.6. ¹⁹F NMR (376 MHz, CDCl₃) δ -58.19 , -63.12 . HRMS (ESI-TOF) m/z : Calcd. for C₄₀H₄₀F₆O₇Na ([M + Na]⁺): 769.2576; found: 769.2543.

1-Adamantanyl 3-O-benzyl-4,6-O-benzylidene-2-O-(methoxycarbonylmethyl)- α -D-mannopyranoside (21 α)—21 α was obtained from **11** by following general procedure I using DPSO as activation agent, 14% ethyl acetate/hexanes, colorless oil (5.2 mg, 16%): $[\alpha]_D^{21}$ $+60.4$ (c 0.26, CHCl₃). ¹H NMR (600 MHz, CDCl₃) δ 7.49 (dd, J = 7.7, 1.6 Hz, 2H), 7.38 – 7.26 (m, 8H), 5.62 (s, 1H), 5.50 (d, J = 1.8 Hz, 1H), 4.90 (d, J = 11.9 Hz, 1H), 4.68 (d, J = 11.9 Hz, 1H), 4.41 (s, 2H), 4.21 (dd, J = 10.5, 5.1 Hz, 1H), 4.18 (t, J = 9.6 Hz, 1H), 4.03 (dd, J = 9.8, 3.2 Hz, 1H), 4.01 (td, J = 9.8, 4.8 Hz, 1H), 3.82 (t, J = 10.3 Hz, 1H), 3.71 (s, 3H), 3.68 – 3.66 (m, 1H), 2.13 (q, J = 3.3 Hz, 3H), 1.86 – 1.74 (m, 6H), 1.61 (q, J = 12.5 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 171.4, 138.7, 137.8, 128.7, 128.3, 128.1, 127.48, 127.47, 126.0, 101.3, 93.5, 80.3, 79.9, 77.0, 74.9, 73.8, 69.4, 68.9, 63.6, 51.7, 42.4, 36.2, 36.1, 30.7, 30.6. HRMS (ESI-TOF) m/z : Calcd. for C₃₃H₄₀O₈Na ([M + Na]⁺): 587.2621; found: 587.2595.

1-Adamantanyl 3-O-benzyl-4,6-O-benzylidene-2-O-(methoxycarbonylmethyl)- β -D-mannopyranoside (21 β)—21 β was obtained from **11** by following general procedure I using DPSO as activation agent, 20% ethyl acetate/hexanes, colorless oil (20.6 mg, 63%): $[\alpha]_D^{21}$ -33.8 (c 1.03, CHCl₃). ¹H NMR (600 MHz, CDCl₃) δ 7.50 – 7.46 (m, 2H), 7.46 – 7.25 (m, 8H), 5.58 (s, 1H), 4.86 – 4.78 (m, 2H), 4.76 (d, J = 0.9 Hz, 1H), 4.58 – 4.50 (m, 2H), 4.24 (dd, J = 10.4, 4.8 Hz, 1H), 4.18 (t, J = 9.6 Hz, 1H), 3.92 – 3.87 (m, 2H), 3.70 (s, 3H), 3.62 (dd, J = 9.9, 3.1 Hz, 1H), 3.30 (td, J = 9.7, 4.8 Hz, 1H), 2.14 (p, J = 3.3 Hz, 3H), 1.84 – 1.71 (m, 6H), 1.66 – 1.55 (m, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 170.9, 138.5, 137.7, 128.8, 128.24, 128.15, 127.6, 127.4, 126.0, 101.4, 94.8, 79.2, 78.1, 77.5, 75.5, 72.2, 70.0, 68.8, 67.4, 51.6, 42.3, 36.1, 30.6. HRMS (ESI-TOF) m/z : Calcd. for C₃₃H₄₀O₈Na ([M + Na]⁺): 587.2621; found: 587.2597.

1,2-O-(2-Benzenesulfenyl-1-phenyl-1,2-ethenediyl)-3-O-benzyl-4,6-O-benzylidene- β -D-mannopyranose (22)—22 was obtained from **5** by following general procedure I using DPSO as activation agent, 8% ethyl acetate/hexanes, colorless oil (7.8 mg, 33%): $[\alpha]_D^{21}$ -83.8 (c 0.185, CHCl₃). ¹H NMR (600 MHz, CDCl₃) δ 7.57 – 7.53 (m, 2H), 7.49 – 7.45 (m, 2H), 7.39 – 7.33 (m, 5H), 7.32 – 7.25 (m, 10H), 7.21 – 7.16 (m, 1H), 5.55 (s, 1H), 5.33 (d, J = 0.8 Hz, 1H), 4.76 (d, J = 12.3 Hz, 1H), 4.69 (d, J = 12.3 Hz, 1H), 4.43 (dd,

$J = 10.4, 4.8$ Hz, 1H), 4.35 (d, $J = 2.8$ Hz, 1H), 4.17 (t, $J = 9.5$ Hz, 1H), 3.90 (t, $J = 10.3$ Hz, 1H), 3.81 (dd, $J = 9.6, 2.9$ Hz, 1H), 3.54 (td, $J = 9.7, 4.9$ Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 140.1, 137.7, 137.2, 135.7, 132.9, 128.99, 128.96, 128.7, 128.6, 128.4, 128.2, 127.74, 127.71, 127.7, 127.4, 127.2, 126.04, 125.99, 101.6, 93.1, 77.8, 75.6, 72.7, 72.0, 68.4, 67.8. HRMS (ESI-TOF) m/z : Calcd. for $\text{C}_{34}\text{H}_{30}\text{O}_6\text{SNa}$ ($[\text{M} + \text{Na}]^+$): 589.1661; found: 589.1645.

Methyl 4-*O*-[4,6-*O*-benzylidene-2-*O*-(2',4'-bis-trifluoromethylphenacyl)-3-*O*-benzyl- β -D-mannopyranosyl]-(1 $\rightarrow$ 4)-2,3-*O*-isopropylidene- α -L-rhamanopyranoside (23 β)—23 β was obtained from **10** by following general procedure II, 17% ethyl acetate/hexanes, colorless oil (19.3 mg, 57%): $[\alpha]_{\text{D}}^{21} -73.4$ (c 0.535, MeOH). ^1H NMR (600 MHz, CDCl_3) δ 7.93 (s, 1H), 7.70 (d, $J = 8.0$ Hz, 1H), 7.59 (d, $J = 8.0$ Hz, 1H), 7.49–7.44 (m, 2H), 7.40–7.26 (m, 8H), 5.50 (s, 1H), 4.96 (d, $J = 0.8$ Hz, 1H), 4.83 (s, 1H), 4.81–4.75 (m, 2H), 4.78 (d, $J = 12.2$ Hz, 1H), 4.70 (d, $J = 12.1$ Hz, 1H), 4.24 (dd, $J = 10.4, 4.8$ Hz, 1H), 4.11 (dd, $J = 7.4, 5.5$ Hz, 1H), 4.07 (d, $J = 5.5$ Hz, 1H), 3.97 (d, $J = 3.0$ Hz, 1H), 3.88 (t, $J = 9.6$ Hz, 1H), 3.80 (t, $J = 10.3$ Hz, 1H), 3.65 (dd, $J = 9.8, 3.0$ Hz, 1H), 3.58 (dd, $J = 10.0, 7.4$ Hz, 1H), 3.55–3.48 (m, 1H), 3.36 (s, 3H), 3.26 (td, $J = 9.8, 4.9$ Hz, 1H), 1.47 (s, 3H), 1.32 (s, 3H), 1.17 (d, $J = 6.1$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 200.5, 140.9, 138.1, 137.3, 132.3 (q, $J = 33.8$ Hz), 129.1, 128.9, 128.7 (q, $J = 33.4$ Hz), 128.4, 128.20, 128.18, 127.8, 127.7, 126.0, 123.7–123.5 (m), 122.9 (q, $J = 272.9$ Hz), 122.8 (q, $J = 273.9$ Hz), 109.4, 101.4, 99.7, 97.8, 78.81, 78.79, 78.21, 78.17, 77.7, 77.3, 76.1, 72.9, 68.6, 67.4, 63.9, 54.8, 27.8, 26.4, 17.4. ^{19}F NMR (376 MHz, CDCl_3) δ -58.27, -63.10. HRMS (ESI-TOF) m/z : Calcd. for $\text{C}_{40}\text{H}_{42}\text{F}_6\text{O}_{11}\text{Na}$ ($[\text{M} + \text{Na}]^+$): 835.2529; found: 835.2495.

Methyl 4-*O*-[4,6-*O*-benzylidene-2-*O*-(methoxycarbonylmethyl)-3-*O*-benzyl- β -D-mannopyranosyl]-(1 $\rightarrow$ 4)-2,3-*O*-isopropylidene- α -L-rhamnopyranoside (24 β)—24 β was obtained from **11** by following general procedure I (50.1 mg, 83%) and from **13** by following general procedure II (26.8 mg, 85%), 20% ethyl acetate/hexanes, colorless oil: $[\alpha]_{\text{D}}^{21} -60.7$ (c 1.045, CHCl_3). ^1H NMR (600 MHz, CDCl_3) δ 7.50–7.46 (m, 2H), 7.41–7.25 (m, 8H), 5.60 (s, 1H), 4.98 (s, 1H), 4.84 (s, 1H), 4.84–4.78 (m, 2H), 4.48–4.39 (m, 2H), 4.25 (dd, $J = 10.4, 4.8$ Hz, 1H), 4.18 (t, $J = 9.6$ Hz, 1H), 4.14 (dd, $J = 7.0, 5.5$ Hz, 1H), 4.07 (d, $J = 5.5$ Hz, 1H), 4.03 (d, $J = 3.0$ Hz, 1H), 3.94 (t, $J = 10.3$ Hz, 1H), 3.70 (s, 3H), 3.67–3.58 (m, 3H), 3.36 (s, 3H), 3.30 (td, $J = 9.8, 4.9$ Hz, 1H), 1.48 (s, 3H), 1.31 (s, 3H), 1.30 (d, $J = 5.8$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 170.7, 138.4, 137.5, 128.8, 128.3, 128.2, 127.6, 127.5, 126.0, 109.4, 101.4, 99.8, 97.8, 78.3, 78.2, 77.9, 77.8, 77.5, 76.1, 72.3, 69.8, 68.5, 67.7, 64.0, 54.8, 51.7, 27.8, 26.4, 17.6. HRMS (ESI-TOF) m/z : Calcd. for $\text{C}_{33}\text{H}_{42}\text{O}_{12}\text{Na}$ ($[\text{M} + \text{Na}]^+$): 653.2574; found: 653.2559.

Methyl 4-*O*-[4,6-*O*-benzylidene-2-*O*-(*t*-butoxycarbonylmethyl)-3-*O*-benzyl- β -D-mannopyranosyl]-(1 $\rightarrow$ 4)-2,3-*O*-isopropylidene- α -L-rhamnopyranoside (25 β)—To a stirred solution of **28** (15.3 mg, 0.027 mmol) in THF (0.4 mL) at 0 °C was added sodium hydride (1.7 mg, 60% suspension in mineral oil, 0.04 mmol). After stirring at 0 °C for 25 min, a solution of *tert*-butyl bromoacetate (8.0 mg, 0.04 mmol) in THF (0.2 mL) was added dropwise. The resulting mixture was stirred at rt for 3 h. After the completion of

reaction, ethyl acetate was added, and the reaction mixture was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. Chromatographic purification (17% ethyl acetate/hexanes) afforded the title compound as a colorless oil (11.6 mg, 63%): $[\alpha]_{\text{D}}^{21} -56.6$ (*c* 0.35, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.52 – 7.47 (m, 2H), 7.45 – 7.23 (m, 8H), 5.61 (s, 1H), 4.97 (s, 1H), 4.86 (s, 1H), 4.83 (s, 2H), 4.35 – 4.26 (m, 2H), 4.28 – 4.18 (m, 2H), 4.16 (dd, *J* = 7.1, 5.4 Hz, 1H), 4.08 (dd, *J* = 5.5, 0.7 Hz, 1H), 4.06 (d, *J* = 3.0 Hz, 1H), 3.94 (t, *J* = 10.3 Hz, 1H), 3.70 – 3.59 (m, 3H), 3.37 (s, 3H), 3.30 (td, *J* = 9.8, 4.8 Hz, 1H), 1.49 (s, 3H), 1.47 (s, 9H), 1.33 (s, 3H), 1.31 (d, *J* = 5.8 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 169.2, 138.6, 137.6, 128.8, 128.3, 128.2, 127.6, 127.4, 126.0, 109.4, 101.3, 100.0, 97.8, 81.1, 78.30, 78.25, 77.8, 77.6, 77.5, 76.1, 72.1, 70.0, 68.6, 67.7, 64.1, 54.9, 28.1, 27.8, 26.4, 17.6. HRMS (ESI-TOF) *m/z*: Calcd. for C₃₆H₄₈O₁₂Na ([M + Na]⁺): 695.3043; found: 695.3026. Compound **25 β** was also obtained from **14** by following general procedure II (1.2 mg, 3%).

Methyl 2,3,6-tri-O-benzyl-4-O-[4,6-O-benzylidene-2-O-(methoxycarbonylmethyl)-3-O-benzyl- α -D-mannopyranosyl]-(1 $\rightarrow$ 4)- α -D-glucopyranoside (26 α**)**—**26 α** was obtained from **11** by following general procedure I, 20% ethyl acetate/hexanes, colorless oil (23.9 mg, 24%): $[\alpha]_{\text{D}}^{21} +26.7$ (*c* 0.375, CHCl₃). ¹H NMR (600 MHz, CDCl₃) δ 7.50 – 7.44 (m, 2H), 7.40 – 7.21 (m, 23H), 5.60 (s, 1H), 5.38 (d, *J* = 1.8 Hz, 1H), 5.06 (d, *J* = 11.4 Hz, 1H), 4.78 (d, *J* = 12.0 Hz, 1H), 4.69 (d, *J* = 12.1 Hz, 1H), 4.63 – 4.57 (m, 4H), 4.56 (d, *J* = 12.1 Hz, 1H), 4.50 (d, *J* = 11.9 Hz, 1H), 4.23 (t, *J* = 9.3 Hz, 1H), 4.13 (d, *J* = 16.6 Hz, 1H), 4.09 (dd, *J* = 9.2, 3.6 Hz, 1H), 3.92 – 3.77 (m, 6H), 3.73 (t, *J* = 2.4 Hz, 1H), 3.70 (m, 3H), 3.57 (s, 3H), 3.55 (dd, *J* = 9.1, 3.4 Hz, 1H), 3.38 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 170.6, 138.7, 138.4, 137.9, 137.8, 137.6, 128.8, 128.5, 128.4, 128.3 (2 carbons), 128.14, 128.13, 128.0, 127.7, 127.59, 127.56, 127.55, 127.45, 126.9, 126.0, 102.2, 101.4, 97.8, 81.2, 80.0, 79.3, 79.2, 77.9, 76.2, 75.2, 73.6, 73.5, 73.2, 69.7, 69.3, 68.8, 68.7, 64.9, 55.3, 51.6. HRMS (ESI-TOF) *m/z*: Calcd. for C₅₁H₅₆O₁₃Na ([M + Na]⁺): 899.3619; found: 899.3608.

Methyl 2,3,6-tri-O-benzyl-4-O-[4,6-O-benzylidene-2-O-(methoxycarbonylmethyl)-3-O-benzyl- β -D-mannopyranosyl]-(1 $\rightarrow$ 4)- α -D-glucopyranoside (26 β**)**—**26 β** was obtained from **11** by following general procedure I (35.6 mg, 42%) and from **13** by following general procedure II (30.3 mg, 59%), 25% ethyl acetate/hexanes, colorless oil: $[\alpha]_{\text{D}}^{21} -14.7$ (*c* 0.32, CHCl₃). ¹H NMR (500 MHz, CDCl₃) δ 7.51 – 7.47 (m, 2H), 7.47 – 7.42 (m, 2H), 7.42 – 7.23 (m, 20H), 7.19 (ddd, *J* = 8.8, 6.0, 3.1 Hz, 1H), 5.53 (s, 1H), 5.01 (d, *J* = 10.6 Hz, 1H), 4.85 – 4.76 (m, 3H), 4.72 – 4.63 (m, 3H), 4.62 (d, *J* = 3.7 Hz, 1H), 4.46 – 4.31 (m, 4H), 4.11 (t, *J* = 9.6 Hz, 1H), 4.03 (dd, *J* = 10.4, 4.8 Hz, 1H), 3.92 (t, *J* = 9.2 Hz, 1H), 3.87 (t, *J* = 9.1 Hz, 1H), 3.75 (d, *J* = 3.0 Hz, 1H), 3.74 – 3.60 (m, 6H), 3.58 – 3.50 (m, 2H), 3.40 (s, 3H), 3.33 (dd, *J* = 9.9, 3.0 Hz, 1H), 3.03 (td, *J* = 9.7, 4.8 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 170.5, 139.3, 138.5, 138.3, 137.6, 137.5, 128.9, 128.6, 128.4, 128.3, 128.2, 128.14, 128.12, 128.07, 128.05, 127.82, 127.76, 127.6, 127.4, 127.3, 126.1, 101.33, 101.26, 98.4, 80.2, 79.1, 78.3, 78.1, 77.8, 77.3, 75.3, 73.63, 73.60, 72.5, 69.9, 69.5, 68.5, 68.4, 67.4, 55.4, 51.6. HRMS (ESI-TOF) *m/z*: Calcd. for C₅₁H₅₆O₁₃Na ([M + Na]⁺): 899.3619; found: 899.3586.

1,2-O-(1-Oxo-ethanediyl)-3-O-benzyl-4,6-O-benzylidene β -D-mannopyranose

(27)—27 was obtained from **14** by following general procedure II (18.1 mg, 70%), 20% ethyl acetate/hexanes, colorless oil: $[\alpha]_D^{21} -24.8$ (c 0.31, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.49 (m, 2H), 7.44 – 7.28 (m, 8H), 5.62 (s, 1H), 5.28 (s, 1H), 4.92 (d, J = 12.4 Hz, 1H), 4.76 (d, J = 12.4 Hz, 1H), 4.60 (d, J = 17.8 Hz, 1H), 4.37 (dd, J = 10.5, 4.9 Hz, 1H), 4.30 (d, J = 17.8 Hz, 1H), 4.16 (t, J = 9.6 Hz, 1H), 3.98 (d, J = 3.2 Hz, 1H), 3.90 (t, J = 10.3 Hz, 1H), 3.80 (dd, J = 9.7, 3.2 Hz, 1H), 3.44 (td, J = 9.7, 4.9 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 164.1, 137.4, 137.0, 129.1, 128.6, 128.3, 128.2, 128.1, 126.0, 101.7, 96.2, 77.6, 75.1, 73.4, 71.4, 68.1, 67.6, 65.3. HRMS (ESI-TOF) m/z : Calcd. for C₂₂H₂₂O₇Na ([M + Na]⁺): 421.1263; found: 421.1280.

Reductive removal of phenacyl-type protecting groups using SmI₂**Methyl 4-O-[4,6-O-benzylidene-3-O-benzyl- β -D-mannopyranosyl]-(1 $\rightarrow$ 4)-2,3-O-isopropylidene- α -L-rhamnopyranoside (28)**

—A solution of SmI₂ in THF (0.1 M in THF, 0.66 mL, 0.07 mmol) was added to a round bottom flask containing **23 β** (10.7 mg, 0.01 mmol) at 0 °C under argon atmosphere. The reaction mixture was stirred at 0 °C for 10 min before it was quenched by adding saturated NaHCO₃ solution (1 mL) at 0 °C. The resulting mixture was diluted with ethyl acetate and washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. Chromatographic purification (33% ethyl acetate/hexanes) afforded the title compound as a colorless oil (5.5 mg, 75%), whose spectral data were identical with the literature values.⁷⁴ $[\alpha]_D^{21} -40.7$ (c 0.3, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.50 (dd, J = 7.6, 2.1 Hz, 2H), 7.42 – 7.27 (m, 8H), 5.61 (s, 1H), 5.02 (d, J = 1.1 Hz, 1H), 4.86 (s, 1H), 4.85 (d, J = 12.4 Hz, 1H), 4.79 (d, J = 12.4 Hz, 1H), 4.29 (dd, J = 10.5, 4.9 Hz, 1H), 4.22 – 4.11 (m, 3H), 4.10 (t, J = 5.5 Hz, 1H), 3.90 (t, J = 10.3 Hz, 1H), 3.73 – 3.62 (m, 3H), 3.36 (s, 3H), 3.33 (dt, J = 9.8, 4.9 Hz, 1H), 1.51 (s, 3H), 1.33 (s, 3H), 1.30 (d, J = 5.5 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 137.9, 137.4, 128.9, 128.4, 128.2, 127.8 (2 carbons), 126.0, 109.4, 101.5, 98.7, 97.8, 78.5, 78.23, 78.20, 76.8, 76.1, 72.4, 70.0, 68.6, 67.0, 63.9, 54.8, 27.8, 26.4, 17.5. HRMS (ESI-TOF) m/z : Calcd. for C₃₀H₃₈O₁₀Na ([M + Na]⁺): 581.2363; found: 581.2370.

Oxidative removal of the methoxycarbonylmethyl protecting group using (1S)-(+)-(10-camphorsulfonyl)oxaziridine

—THF (0.3 mL) was added to a solution of KHMDS in toluene (0.5 M, 0.17 mL, 0.09 mmol) at –78 °C under argon. To the resulting mixture was added a solution of **24 β** (34.4 mg, 0.06 mmol) in THF (0.45 mL) dropwise over 15 min. After stirring at the same temperature for 30 min, (1S)-(+)-(10-camphorsulfonyl)-oxaziridine (39.3 mg, 0.17 mmol) was added in one portion and the reaction mixture was stirred at –78 °C for another 1 h before it was quenched with saturated NaHCO₃ solution (1 mL). After warming to rt, the mixture was diluted with ethyl acetate and washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. Chromatographic purification (33% ethyl acetate/hexanes) afforded the title compound as a colorless oil (19.6 mg, 64%).

Computational Methods

Geometry optimization of all four structures were performed using density functional theory (DFT) Becke's three-parameter hybrid function with the non-local correlation of Lee-Yang-Parr (B3LYP) method in gas phase.^{65–68} The corresponding harmonic vibrational

frequencies were computed at the same level of theory to characterize them as minima (no imaginary frequencies) with help of Gaussian09W package program.⁶⁹ All of above calculations were done using 6-31+G(d,p) basis set.^{75–78} The Gibbs free energies differences reported include thermal correction at B3LYP/6-31+G(d,p) level of theory. All the structures were built using GaussView 5.0.9.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the NIH (GM62160) for support of this work, and acknowledge support from the NSF (MRI-084043) for the purchase of the 600 MHz NMR spectrometer in the Lumigen Instrument Center at Wayne State University. We thank Harsha Amarasekara, Wayne State University, for the computations.

References

1. Capon, B.; McManus, SP. Neighboring Group Participation. Plenum; New York: 1976.
2. Frush HL, Isbell HS. J Research Natl Bur Standards. 1941; 27:413–428.
3. Ranade SC, Demchenko AV. J Carbohydr Chem. 2013; 32:1–43.
4. Lemieux RU. Adv Carbohydr Chem. 1954; 9:1–57. [PubMed: 13217906]
5. Paulsen H, Herold CP. Chem Ber. 1970; 103:2450–2462.
6. Crich D, Dai Z, Gastaldi S. J Org Chem. 1999; 64:5224–5229.
7. Nukada T, Berces A, Zgierski MZ, Whitfield DM. J Am Chem Soc. 1998; 120:13291–13295.
8. Yang Z, Lin W, Yu B. Carbohydr Res. 2000; 329:879–884. [PubMed: 11125831]
9. Kong F. Carbohydr Res. 2007; 342:345–373. [PubMed: 17109835]
10. Bochkov, AF.; Zaikov, GE. Chemistry of the O-Glycosidic Bond. Pergamon; Oxford: 1979.
11. Fraser-Reid, B.; López, JC. Handbook of Chemical Glycosylation. Demchenko, AV., editor. Wiley-VCH; Weinheim: 2008. p. 381-415.
12. Winstein S, Grunwald E, Ingraham LL. J Am Chem Soc. 1948; 70:821–828.
13. Komarova, BS.; Ustyuzhania, NE.; Tsvetkov, YE.; Nifantiev, NE. Modern Synthetic Methods in Carbohydrate Chemistry; From Monosaccharides to Complex Glycoconjugates. Werz, DB.; Vidal, S., editors. Wiley; Weinheim: 2014. p. 125-160.
14. Smoot JT, Pornsuriyasak P, Demchenko AV. Angew Chem Int Ed. 2005; 44:7123–7126.
15. Smoot JT, Demchenko AV. J Org Chem. 2008; 73:8838–8850. [PubMed: 18939875]
16. Kim JH, Yang H, Park J, Boons GJ. J Am Chem Soc. 2005; 127:12090–12097. [PubMed: 16117550]
17. Fascione MA, Kilner CA, Leach AG, Turnbull WB. Chem Eur J. 2012; 18:321–333. [PubMed: 22140005]
18. Ma Y, Lian G, Li Y, Yu B. Chem Commun. 2011; 47:7515–7517.
19. Boltje TJ, Kim JH, Park J, Boons GJ. Org Lett. 2011; 13:284–287. [PubMed: 21158475]
20. Cox DJ, Singh GP, Watson AJA, Fairbanks AJ. Eur J Org Chem. 2014:4624–4642.
21. Singh GP, Watson AJA, Fairbanks AJ. Org Lett. 2015; 17:4376–4379. [PubMed: 26308903]
22. Buda S, Nawój M, Golebiowska P, Dyduch K, Michalak A, Mlynarski J. J Org Chem. 2015; 80:770–780. [PubMed: 25521426]
23. Buda S, Golebiowska P, Mlynarski J. Eur J Org Chem. 2013:3988–3991.
24. Komarova BS, Orekhova MV, Tsvetkov YE, Nifantiev NE. Carbohydr Res. 2014; 384:70–86. [PubMed: 24368161]
25. Lourenco EC, Ventura MR. Tetrahedron. 2013; 69:7090–7097.

26. Baek JY, Lee BY, Jo MG, Kim KS. *J Am Chem Soc.* 2009; 131:17705–17713. [PubMed: 19908841]
27. Kalikanda J, Li Z. *J Org Chem.* 2011; 76:5207–5218. [PubMed: 21574599]
28. Kim KS, Suk DH. *Top Curr Chem.* 2011; 301:109–140. [PubMed: 21229347]
29. De Meo C, Kamat MN, Demchenko AV. *Eur J Org Chem.* 2005:706–711.
30. Demchenko AV, Rousson E, Boons GJ. *Tetrahedron Lett.* 1999; 40:6523–6536.
31. Baek JY, Kwon HW, Myung SJ, Park JJ, Kim MY, Rathwell DCK, Jeon HB, Seeberger PH, Kim KS. *Tetrahedron.* 2015; 71:5315–5320.
32. Pedersen CM, Marinescu LG, Bols M. *CR Chimie.* 2011; 14:17–43.
33. Walvoort MTC, Dinkelaar J, van den Bos LJ, Lodder G, Overkleeft HS, Codée JDC, van der Marel GA. *Carbohydr Res.* 2010; 345:1252–1263. [PubMed: 20347068]
34. Williams RJ, McGill NW, White JM, Williams SJ. *J Carbohydr Chem.* 2010; 29:236–263.
35. Jensen HH, Bols M. *Acc Chem Res.* 2006; 39:259–265. [PubMed: 16618093]
36. Smith DM, Woerpel KA. *Org Biomol Chem.* 2006; 4:1195–1201. [PubMed: 16557303]
37. Heuckendorff M, Pedersen CM, Bols M. *Chem Eur J.* 2010; 16:13982–13994. [PubMed: 21132699]
38. Morimoto Y, Shirahama H. *Tetrahedron.* 1997; 53:2013–2024.
39. Chamberland S, Ziller JW, Woerpel KA. *J Am Chem Soc.* 2005; 127:5322–5323. [PubMed: 15826161]
40. Garcia A, Otte DAL, Salamant WA, Sanzone JR, Woerpel KA. *Angew Chem Int Ed.* 2015; 54:3061–3064.
41. Garcia A, Otte DAL, Salamant WA, Sanzone JR, Woerpel KA. *J Org Chem.* 2015; 80:4470–4480. [PubMed: 25806832]
42. van Boeckel CAA, Beetz T, van Aelst SF. *Tetrahedron.* 1984; 40:4097–4107.
43. Bohé L, Crich D. *Carbohydr Res.* 2015; 403:48–59. [PubMed: 25108484]
44. Yasomanee JP, Demchenko AV. *Angew Chem Int Ed.* 2014; 53:10453–10456.
45. Pistorio SG, Yasomanee JP, Demchenko AV. *Org Lett.* 2014; 16:716–719. [PubMed: 24471826]
46. Wilen SH, Delguzzo L, Saferstein R. *Tetrahedron.* 1987; 43:5089–5094.
47. Crich D, Hu T, Cai F. *J Org Chem.* 2008; 73:8942–8953. [PubMed: 18939876]
48. Brunckova J, Crich D. *Tetrahedron.* 1995; 51:11945–11952.
49. Crich D, Mataka J, Sun S, Lam K-C, Rheingold AR, Wink DJ. *Chem Commun.* 1998:2763–2764.
50. Crich D, Mataka J, Zakharov LN, Rheingold AL, Wink DJ. *J Am Chem Soc.* 2002; 124:6028–6036. [PubMed: 12022836]
51. Liang H, MacKay M, Grindley TB, Robertson KN, Cameron TS. *Can J Chem.* 2010; 88:1154–1174.
52. Huang M, Retailleau P, Bohé L, Crich D. *J Am Chem Soc.* 2012; 134:14746–14749. [PubMed: 22920536]
53. Adero PO, Furukawa T, Huang M, Mukherjee D, Retailleau P, Bohé L, Crich D. *J Am Chem Soc.* 2015; 137:10336–10345. [PubMed: 26207807]
54. Chen BC, Zhou P, Davis FA, Ciganek E. *Org React.* 2003; 62:1–356.
55. Lemieux RU, Huber G. *Can J Chem.* 1953; 31:1040–1047.
56. Crich D, Cai W, Dai Z. *J Org Chem.* 2000; 65:1291–1297. [PubMed: 10814088]
57. Franck RW, Marzabadi CH. *J Org Chem.* 1998; 63:2197–2208.
58. Dios A, Geer A, Marzabadi CH, Franck RW. *J Org Chem.* 1998; 63:6673–6679.
59. Krumper JR, Salamant WA, Woerpel KA. *J Org Chem.* 2009; 74:8039–8050. [PubMed: 19813702]
60. Schultz JC, Houle FA, Beauchamp JL. *J Am Chem Soc.* 1984; 106:3917–3927.
61. Deslongchamps, P. *Stereoelectronic Effects in Organic Chemistry.* Pergamon; Oxford: 1983.
62. Ramsey BG, Taft RW. *J Am Chem Soc.* 1966; 88:3058–3063.
63. Borch RF. *J Am Chem Soc.* 1968; 90:5303–5305.

64. Dusseau CHV, Schaafsma SE, Steinberg H, de Boer TJ. *Tetrahedron Lett.* 1969; 10:467–470.
65. Hohenberg P, Kohn W. *Phys Rev.* 1964; 136:B864–870.
66. Feller D. *J Chem Phys.* 1990; 93:579–590.
67. Becke AD. *J Chem Phys.* 1993; 98:5648–5652.
68. Lee C, Yang W, Parr RG. *Phys Rev B.* 1988; 37:785–789.
69. Frisch, M.; Trucks, G.; Schlegel, H.; Scuseria, G.; Robb, M.; Cheeseman, J.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H.; Izmaylov, A.; Bloino, J.; Zheng, G.; Sonnenberg, J.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J.; JA; Peralta, J.; Ogliaro, F.; Bearpark, M.; Heyd, J.; Brothers, E.; Kudin, K.; Staroverov, V.; Keith, T.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J.; Iyengar, S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J.; Klene, M.; Knox, J.; Cross, J.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R.; Yazyev, O.; Austin, A.; Cammi, R.; Pomelli, C.; Ochterski, J.; Martin, R.; Morokuma, K.; Zakrzewski, V.; Voth, G.; Salvador, P.; Dannenberg, J.; Dapprich, S.; Daniels, A.; Farkas, O.; Foresman, J.; Ortiz, J.; Cioslowski, J.; Fox, D. *p Gaussian 09 revision D01*. Gaussian, Inc; Wallingford, CT: 2013.
70. Kim JH, Yang H, Boons GJ. *Angew Chem Int Ed.* 2005; 44:947–949.
71. Kim J-H, Yang H, Khot V, Whitfield D, Boons G-J. *Eur J Org Chem.* 2006:5007–5028.
72. Jung ME, Piizzi G. *Chem Rev.* 2005; 105:1735–1766. [PubMed: 15884788]
73. Kumar R, Whitfield DM. *J Org Chem.* 2012; 77:3724–3739. [PubMed: 22428576]
74. Crich D, Jayalath P, Hutton TK. *J Org Chem.* 2006; 71:3064–3070. [PubMed: 16599600]
75. Clark T, Chandrasekhar J, Spitznagel GW, Schleyer PVR. *J Comput Chem.* 1983; 4:294–301.
76. Spitznagel GW, Clark T, Chandrasekhar J, Schleyer PVR. *J Comput Chem.* 1982; 3:363–371.
77. Hariharan PC, Pople JA. *Theoretica Chim Acta.* 1973; 28:213–222.
78. Hehre WJ, Ditchfield R, Pople JA. *J Chem Phys.* 1972; 56:2257–2261.

Figure 1.
Dialkoxycarbenium Ion Configurations

$$\Delta G = -14.85 \text{ kcal.mol}^{-1}$$

The diagram illustrates the equilibrium between two chemical structures. On the left is an open-chain structure: a five-membered ring containing one oxygen atom and a carbonyl group (C=O). A methoxy group (-OCH₃) is attached to the carbon adjacent to the carbonyl. A double-headed arrow indicates equilibrium with the structure on the right. The structure on the right is a cyclic oxazolidinone, a five-membered ring with one oxygen atom and a positive charge on the nitrogen atom. A methoxy group is also attached to the ring.

$$\Delta G = -13.11 \text{ kcal.mol}^{-1}$$

J Org Chem. Author manuscript; available in PMC 2016 December 18.

Scheme 1.
 Synthesis of thioglycosides **5–7** and sulfoxides **8–10**.

Scheme 2. Synthesis of the 2-*O*-(methoxycarbonylmethyl) derivatives **11–15**.

Scheme 3.

Deprotection Methods for Bis(trifluoromethyl)phenacyl and Methoxycarbonylmethyl Ethers and Synthesis of an Authentic Sample of Glycoside **25β**.

Scheme 4.

Stereoselective Glucosylation with 2-*O*-(Ethoxycarbonylbenzyl) Protected Donors and the Structures of Possible Intermediates Arising from Participation.^{70–71}

Table 1

Glycosylation Reactions.

Entry	Donor	Acceptor	Activation	Products (% yield)
1	5	16	DPSO, Tf ₂ O, TTBP	22 (33)
2	7	16	BSP, Tf ₂ O, TTBP	20 (62), 3.8:1 β:α
3	10	16	Tf ₂ O, TTBP	20 (62), 7.9:1 β:α
4	10	17	Tf ₂ O, TTBP	23 (57), β-only
5	11	16	BSP, Tf ₂ O, TTBP	21 (79), 5:1 β:α
6	11	17	BSP, Tf ₂ O, TTBP	24 (83), β-only
7	11	18	BSP, Tf ₂ O, TTBP	26 (87), 2.6:1 β:α
8	12	17	Tf ₂ O, TTBP	24 (85), β-only
9	12	18	Tf ₂ O, TTBP	26 (59), β-only
10	14	17	Tf ₂ O, TTBP	25 (3), β-only + 27 (70)